免疫代谢生物标志物用于1型糖尿病中部分缓解
Laia Gomez-Muñoz1, Juan Dominguez-Bendala2, Ricardo L Pastori2
1Immunology Section, Germans Trias i Pujol Research Institute, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.
Trends in endocrinology and metabolism: TEM
|November 10, 2023
概括
1型糖尿病 (T1DM) 的蜜月阶段具有治疗潜力,但缺乏生物标志物. 本综述探讨了新的生物标志物,以了解和管理这种缓解阶段.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
- 代谢研究研究 代谢研究
背景情况:
- 1型糖尿病 (T1DM) 患者在诊断和胰岛素开始后,经常经历过渡性部分缓解 (PR) 阶段或蜜月阶段.
- 这个PR阶段与有益的免疫调节和β细胞保护机制有关,呈现出治疗窗口.
- 目前对PR阶段的表征受到缺乏可靠生物标志物的阻碍.
研究的目的:
- 对T1DM蜜月阶段的新型预测和监测生物标志物的文献进行审查.
- 阐明PR的代谢,表观遗传和免疫学基础.
- 讨论外围生物标志物的临床应用,反映出阻止β细胞自身免疫力的努力.
主要方法:
- 关于T1DM PR生物标志物的当前研究的文献综述.
- 对调查代谢,表观遗传和免疫学标记的研究进行分析.
- 综合与临床适用性相关的发现.
主要成果:
- 新兴的生物标志物正在被确定以表征T1DM的PR阶段.
- 这些生物标志物为代谢,表观遗传和免疫因素的复杂相互作用提供了洞察力.
- 外围标记物在反映身体试图保护β细胞免受自身免疫作用方面表现出有希望.
结论:
- 生物标志物发现对于理解和潜在地延长T1DM蜜月阶段至关重要.
- 外围生物标志物可以为临床管理和治疗策略提供有价值的信息.
- 对这些生物标志物的进一步研究可能会改善T1DM患者的治疗结果.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Diabetes: Symptoms, Diagnosis, and Complications
556
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
556
Diabetes: Management and Pharmacotherapy
290
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
290
Insulin: Dosing Regimen and Adverse Effects
184
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
184


